STOCK TITAN

Camp4 Therapeutics Corp. Stock Price, News & Analysis

CAMP Nasdaq

Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.

CAMP4 Therapeutics Corporation (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. The CAMP news feed highlights how the company advances its antisense oligonucleotide (ASO) pipeline, progresses clinical and preclinical programs, and enters strategic collaborations.

Readers can follow CAMP4’s updates on its SYNGAP1-related disorders program, including announcements about GLP toxicology studies for CMP-SYNGAP-01, translational data in humanized mouse models and non-human primates, and plans for Phase 1/2 clinical trial applications. News items also cover the company’s Urea Cycle Disorders program and the CMP-CPS-001 (CMP-001) Phase 1 trial, where CAMP4 has reported safety and pharmacokinetics data from single and multiple ascending dose cohorts in healthy volunteers.

CAMP4’s news flow includes financial and corporate updates such as private placements, underwritten offerings of common stock, and use of proceeds to support development of its product candidates. The company also reports on strategic agreements, including a research, collaboration and license agreement with GSK to discover and develop ASO drug candidates for neurodegenerative and kidney disease indications using CAMP4’s RAP Platform.

In addition, CAMP4 issues press releases on scientific presentations at major meetings, corporate highlights, and inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this news page to review CAMP4’s reported milestones, research progress, and financing activities related to its regulatory RNA-targeting therapeutic strategy.

Rhea-AI Summary

CalAmp (Nasdaq: CAMP) will release its fiscal 2023 first quarter financial results post-market on June 23, 2022. The company will also host a conference call at 5:00 p.m. Eastern time the same day to discuss these results. Interested investors can access the call via webcast or by phone using the provided conference ID. CalAmp provides a data-driven solutions ecosystem aiming to enhance operational performance for organizations in sectors like transportation and logistics, with over one million software subscribers and 10 million edge devices deployed globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences earnings
-
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced the appointment of Brennen Carson as Chief Revenue Officer (CRO) to enhance growth in the transportation and logistics market. Carson, with over 15 years of experience in SaaS sales, previously served as Senior VP of Sales at Idelic, where he significantly increased revenue. His appointment aims to accelerate revenue streams and implement customer-centric sales strategies. CEO Jeff Gardner remarked on Carson's expertise in fleet telematics as a great asset for driving revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
management
-
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) has announced the election of Henry Maier as the new Independent Chair of its Board of Directors, effective from the 2022 Annual Meeting. Maier succeeds Amal Johnson, who will not seek re-election. With over 40 years in the transportation industry, including leadership at FedEx Ground, Maier brings valuable insights and experience. He aims to guide CalAmp’s growth and innovation strategies, focusing on the opportunities within the evolving transportation and logistics market. Johnson expressed confidence in CalAmp's leadership moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
management
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced the launch of its Supply Chain Visibility solution through its subsidiary, Tracker Network, for pan-European logistics operators. This real-time cargo tracking system is crucial for high-value and high-risk shipments, particularly in industries like pharmaceuticals and food. The solution leverages wireless sensors to monitor shipment conditions and offers compliance documentation. It aims to enhance supply chain efficiency and reduce spoilage, addressing challenges highlighted during the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
none
-
Rhea-AI Summary

CalAmp (Nasdaq: CAMP), a leader in connected intelligence, announced that CEO Jeff Gardner and CFO Kurt Binder will meet with investors at Oppenheimer’s 7th Annual Emerging Growth Conference on May 10, 2022. This virtual event aims to enhance operational performance through a data-driven solutions ecosystem. Portfolio managers and analysts interested in scheduling meetings should contact their Oppenheimer representative. CalAmp delivers solutions that monitor and recover essential assets across multiple sectors, boasting over one million software subscribers and ten million edge devices deployed worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced that 272 Capital Master Fund Ltd. has nominated six candidates for election to its Board of Directors at the upcoming 2022 Annual Meeting. This comes amid the company’s ongoing transformation from a telematics-based business to a software and subscription services model. CalAmp reported a significant increase in Software and Subscription Services revenue, which rose 19% year-over-year in Q4 2022, now representing 60% of total revenues. The Board is reviewing the nominees while emphasizing its commitment to shareholder value creation and ongoing engagement with stockholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.12%
Tags
none
-
Rhea-AI Summary

CalAmp reported a 19% increase in Software and Subscription Services revenue year-over-year, reaching $41 million, representing 60% of total revenue. Remaining Performance Obligations rose 47% to $200 million

However, total revenue for the fourth quarter was $68.4 million, slightly down from the prior quarter, and annual revenue decreased from $308.6 million to $295.8 million. The company reported a GAAP net loss of $9.2 million for the quarter and $31.1 million for the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced it will release its fiscal 2022 fourth quarter and full-year financial results on April 28, 2022, after market close. The company will host a conference call to discuss these results at 5:00 p.m. Eastern Time, accessible via webcast or by dialing in. CalAmp specializes in connected intelligence, helping businesses track and recover assets through real-time insights. The company supports various sectors including transportation, logistics, and automotive, boasting over one million subscribers and 20 million products deployed globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
conferences earnings

FAQ

What is the current stock price of Camp4 Therapeutics (CAMP)?

The current stock price of Camp4 Therapeutics (CAMP) is $4.08 as of May 6, 2026.

What is the market cap of Camp4 Therapeutics (CAMP)?

The market cap of Camp4 Therapeutics (CAMP) is approximately 206.7M.